Online inquiry

IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15379MR)

This product GTTS-WQ15379MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD37 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001040031.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 951
UniProt ID P11049
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15379MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14401MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ10974MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ13476MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PRTX-100
GTTS-WQ6511MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CX-072
GTTS-WQ2428MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 145
GTTS-WQ11866MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MK-7684
GTTS-WQ13042MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ6556MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA D2E7
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW